Acute regimen-related toxicity (RRT) is minimal in reduced-intensity stem-cell transplantation (RIST). However, the Seattle RRT grading (Bearman et al), developed in the context of conventional-intensity transplantation, is frequently applied to RIST. We compared the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0 with the Seattle criteria after RIST in 86 patients. RRT within 30 days of transplant graded by both sets of criteria were significantly associated with the outcome confirming the predictive value of both the systems. A total of 15 patients died of disease progression, and 12 of transplant-related mortality: RRT (n ¼ 2), graft-versus-host disease (GVHD) (n ¼ 7), infection (n ¼ 1), and others (n ¼ 2). GVHD-related deaths primarily resulted from infections after steroid treatment (n ¼ 6) and bronchiolitis obliterans (n ¼ 1). This study shows that NCI-CTC is appropriate in toxicity evaluation of RIST, and that its application to RIST enables a toxicity comparison between RIST and other types of cancer treatments. Since GVHD is a significant problem in RIST, modifications are required to evaluate immunological complications following RIST.
The recognition and grading of toxicity caused by RIST is important in practice and in designing clinical trials.
After conventional-intensity stem-cell transplantation (CIST), patients can die of disease progression or complications of therapy. RRT is toxicity that is directly attributable to the conditioning regimen, but usually excludes graft-versus-host disease (GVHD), infection, and hemorrhage. It is often difficult to separate RRT from other toxicities. The Seattle group proposed a toxicity grading system specifically for allogeneic HSCT based upon a retrospective review of 195 patients who underwent CIST. 7 RRT in RIST is minimal and a significant proportion of morbidity and mortality is secondary to GVHD. 8 However, the Seattle criteria have been used to evaluate RIST.
The National Cancer Institute Common Toxicity Criteria version 2.0 (NCI-CTC ver. 2.0) has been widely used for development and evaluation of chemotherapeutic agents. If NCI-CTC ver. 2.0 can be applied to RIST, toxicity comparison between RIST and various other cancer treatments would be possible. We studied 86 patients who underwent RIST to see if NCI-CTC ver. 2.0 could be used to predict transplant-related mortality (TRM) and overall survival (OS) after RIST.
Patients and methods

Patients
The medical records of all of the patients (n ¼ 86) who underwent RIST at the National Cancer Center Hospital between January 1999 and April 2002 were reviewed. All patients and donors gave their written informed consent in accordance with the requirements of the Institutional Review Board of the National Cancer Center Hospital.
The median age was 51 years (range, 4-67). The underlying disease was AML (n ¼ 26), lymphoma (n ¼ 21), MDS (n ¼ 11), CML (n ¼ 5), ALL (n ¼ 2), other hematologic diseases (n ¼ 3), and solid tumors (n ¼ 18). The hematological malignancies were refractory to chemotherapy in 33 cases, and were in remission or sensitive to treatment in the remaining 35 cases. All of the patients with solid tumors were refractory to conventional treatments.
Preparative regimens
The preparative regimens comprised busulfan 4 mg/kg daily for 2 days with fludarabine 25 mg/kg daily for 6 days (n ¼ 64) 9 or cladribine 0.11 mg/kg daily for 6 days (n ¼ 22).
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Rabbit antithymocyte globulin (ATG, Thymoglobulin, IMTIX-SANGSTAT, Lyons, France) 2.5 mg/kg for 2 or 4 days and TBI (4 Gy) were added to the preparative regimen in 49 and three patients, respectively.
Stem-cell source
A total of 64 patients had an HLA-identical related donor and 17 had a one-locus mismatched related donor. 10 Peripheral blood was used for these 81 patients. Five patients received bone marrow from a matched unrelated donor (MUD).
Prophylaxis and treatment of GVHD
Patients who were transplanted from an HLA-identical related donor received cyclosporin alone (3 mg/kg). Those who were transplanted from an HLA-mismatched related donor or MUD received cyclosporin and short-course methotrexate. The diagnosis of GVHD was made on clinical grounds in conjunction with biopsy of the skin and digestive tract. Acute and chronic GVHD were graded according to the consensus criteria. 11, 12 Grade II-IV acute GVHD was treated with 2 mg/kg/day of methylprednisolone in addition to cyclosporin.
Management of infections
All of the patients stayed in reverse isolation in a laminar airflow-equipped room, and received prophylaxis with trimethoprim/sulfamethoxazole or pentamidine inhaler, ciprofloxacin, and fluconazole against Pneumocystis carinii, bacterial, and fungal infection, respectively. Herpes virus prophylaxis with acyclovir was also given as previously described. 13 CMV pp65 antigenemia was routinely monitored once a week. When antigenemia was detected, preemptive therapy with ganciclovir was initiated as previously reported. 14 
Toxicity grading
The Seattle criteria assess post transplant RRT in eight organs: the heart, bladder, kidneys, lungs, liver, mucosa, central nervous system (CNS), and gut. As the criteria exclusively assess RRT, they exclude adverse events attributable to GVHD and infection. Similarly, renal failure is excluded when it coincides with the administration of known nephrotoxic agents. RRT was graded with the Seattle criteria on the day of initiation of conditioning regimens and days 0, 7, 14, and 28 (and on day 100 for lungs) post transplant (Table 1) . NCI-CTC ver. 2.0 assesses more than 260 adverse events in 24 organ systems. To make a comparison, 16 items in NCI-CTC ver. 2.0 equivalent to those in the Seattle criteria were regraded. These included arrhythmia, cardiovascular dysfunction, hematuria, renal dysfunction/creatinine levels, lung toxicity, serum levels of bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), weight gain/ascites, neurological dysfunction, mucositis, and diarrhea ( Table 2 ). All of the observed adverse events were evaluated daily with NCI-CTC ver. 2.0 from the day of initiation of conditioning regimens until day 30 post transplant (and on day 100 for lungs).
Two or more independent physicians graded RRT based on the medical records. If there was discordance between their diagnoses, another physician (MK) made a final diagnosis.
Statistical analysis
The probability of OS was determined with the KaplanMeier method as of June 31, 2002. The median follow-up period after transplantation was 252 days (range, 82-1046 days). Surviving patients were censored on the last day of follow-up.
A univariate analysis using the w 2 test and MannWhitney test were performed to identify the risk factors for RRT. A multivariable Cox proportional-hazards analysis was conducted to determine whether the development of RRT was independent of other clinical variables in predicting overall mortality. In RIST for solid tumors and malignant lymphoma, some lesions persist following preparative regimens. Sizes of these lesions frequently show a transient increase until the development of alloimmune responses. When patients die without disease progression, it is difficult to determine whether these deaths are attributable to disease progression or TRM. We therefore used overall mortality instead of nonrelapse deaths.
Clinical variables examined in a univariate analysis were entered in a backward, stepwise Cox proportional-hazards model to identify predictors of mortality. Variables with a P-value of less than 0.50 were entered into the model, and those with a P-value of less than 0.10 were retained. The P-values less than 0.05 were considered to be significant.
Results
Toxicity grading
Grade 3-4 toxicity by the Seattle criteria was observed in the lung (5%), CNS (2%), kidney (1%), and heart (1%) ( Table 3 ). The maximal toxicity of grades 0, 1, 2, 3, and 4 was noted in eight (9%), 38 (44%), 35 (41%), four (5%), and one patient (1%), respectively.
Grade 3-4 toxicity by NCI-CTC ver. 2.0 was observed in all of the organs (Table 4) : liver (31%), lung (21%), stomatitis (13%), gastrointestinal tract (9%), heart (6%), CNS (6%), kidney (2%), and bladder (1%). The maximal toxicity of grades 0, 1, 2, 3, and 4 was observed in two Evaluation of RRT following RIST M Sakiyama et al Table 1 Regimen-related toxicity according to the Seattle criteria Severe ulceration and/or mucositis requiring preventive intubation; or resulting in documented aspiration pneumonia with or without intubation GI toxicity Watery stools 4500 ml but o2000 ml every day not related to infection Watery stools 42000 ml every day not related to infection; or macroscopic hemorrhagic stools with no effect on cardiovascular status not caused by infection; or subileus not related to infection
Ileus requiring nasogastric suction and/or surgery and not related to infection; or hemorrhagic enterocolitis affecting cardiovascular status and requiring transfusion
Grade IV regimen-related toxicity is defined as fatal toxicity. CXR ¼ chest X ray; i.v. ¼ intravenous; CNS ¼ central nervous system; GI ¼ gastrointestinal; CHF ¼ congestive heart failure. There were 10 cases of the 'up-staging' of the toxicity from the Seattle criteria to NCI-CTC version 2.0: liver (n ¼ 6), and kidney (n ¼ 4).
Evaluation of RRT following RIST M Sakiyama et al
Association between toxicity grading and survival following RIST
A total of 27 patients died: 16 of disease progression (19%) and 11 of TRM (13%). The 11 patients who died of TRM had the maximal toxicity of grade 2 (n ¼ 1), grade 3 (n ¼ 6), and grade 4 (n ¼ 4) by NCI-CTC ver. 2.0, which was also graded with the Seattle criteria to be grade 1 (n ¼ 3), grade 2 (n ¼ 5), grade 3 (n ¼ 2), and grade 4 (n ¼ 1). The causes of TRM were GVHD/steroid-related infection (n ¼ 6), GVHD (bronchiolitis obliterans) (n ¼ 1), infection (n ¼ 2), and Table 3 Toxicity grading using the Seattle criteria in 86 patients undergoing RIST   Grade  0  1  2  3  4   Gut  69  17  0  0  0  Stomatitis  47  29  10  0  0  Central nervous system  78  4  2  2  0  Liver  23  31  31  1  0  Lung  75  4  3  3  1  Kidney  51  31  3  1  0  Bladder  84  2  0  0  0  Heart  70  8  7  1  0   Maximal grades  8  38  35  4  1   Table 4 Toxicity grading using NCI-CTC ver. 2.0 in 86 patients undergoing RIST 5  27  27  22  5  Lung  56  12  0  17  1  Kidney  47  26  11  2  0  Bladder  61  23  1  1  0  Heart  72  6  3  3  2 Maximal grades 2 16 25 35 8 Figure 1 Overall survival evaluated by the Seattle criteria. Five patients had grade 3-4 toxicity in at least one organ, of whom three died (60%). The estimated 1-year OS was 25.0% (95% confidence interval (CI) 0.0-61.7%). In contrast, of the 81 patients with grade 0-2 toxicity in all the organ systems, eight died (9.9%). The estimated 1-year OS was 74.2% (95% CI, 64.2-84.2%). The one-year OS was significantly lower in the patients with grade 3-4 toxicity (P ¼ 0.0037). Evaluation of RRT following RIST M Sakiyama et al others (n ¼ 2). Maximal grades of GVHD in fatal cases were IV (n ¼ 1), III (n ¼ 1), II (n ¼ 3), and I (n ¼ 2). Figure 1 demonstrates the association between the maximal toxicity of the Seattle criteria and OS. Five patients had grade 3-4 toxicity in at least one organ, of whom three died (60%). Estimated 1-year OS was 25.0% (95% confidence interval (CI) 0.0-61.7%). In contrast, of the 81 patients with grade 0-2 toxicity in all the organ systems, eight died (9.9%). The estimated 1-year OS was 74.2% (95% CI, 64.2-84.2%). The 1-year OS was significantly lower in the patients with grade 3-4 toxicity (P ¼ 0.0037). Figure 2 demonstrates the association between the maximal toxicity of NCI-CTC ver. 2.0 and OS. In all, 43 patients had grade 3-4 toxicity in at least one organ, of whom 10 patients (23.2%) died of TRM. The estimated 1-year OS was 64.7% (95% CI, 50.2-79.2%). In contrast, of the remaining 43 patients with grade 2 toxicity in all the organ systems, one died of GVHD, resulting in 78.5% (95% CI, 64.8-92.2%) of estimated 1-year OS and 8.8% of TRM. The 1-year OS was significantly lower in the patients with grade 3-4 toxicity (P ¼ 0.037).
Grades
0 1 2 3 4 G u t 5 0 1 8 1 0 7 1 Stomatitis 35 8 32 1 0 Central nervous system 74 5 2 2 3 Liver
Variables influencing RRT
No variables were found to be associated with RRT of NCI-CTC ver. 2.0 by univariate (Table 5 ) or multivariate analysis.
Variables influencing overall survival
Patients who survived longer than 30 days were included in this analysis. Multivariate analysis showed that survival was significantly different between unrelated vs related donors (hazard ratio 7.5, 95% CI 1.7-32.8, P ¼ 0.0074), HLA-mismatched vs matched (hazard ratio 3.8, 95% CI 1.1-12.9, P ¼ 0.0295), and the maximal toxicity grade 3-4 vs grade 2-3 of NCI-CTC ver. 2.0 within day 30 post transplant (hazard ratio 3.0, 95% CI 1.2-7.3, P ¼ 0.0177).
Discussion
Evaluation of RRT after RIST is not uniform. As a result, toxicity grades vary among studies (Table 6 ) (2-4, 6, 15-18). Our study shows that both the Seattle criteria and NCI-CTC ver. 2.0 are significantly associated with outcome, and have predictive value.
The prognosis of grade 3 by the Seattle criteria is comparable to that of grade 4 by NCI-CTC ver. 2.0, and the prognosis of grade 2 by the Seattle criteria is comparable to that of grade 3 by NCI-CTC ver. 2.0 (Figures 1 and 2) . However, neither criteria can offer a cutoff to predict death since the sensitivity and specificity are insufficient; the threshold of pgrade 2 by Seattle criteria and pgrade 3 by NCI-CTC ver. 2.0 would be sensitive but not specific to predict TRM, whereas the threshold of Xgrade 3 by the Seattle criteria and Xgrade 4 by NCI-CTC ver. 2.0 would be specific but not sensitive. These findings suggest that these criteria need to be modified for use in RIST.
There are two types of complications associated with allogeneic HSCT. One is the organ toxicity directly caused by preparative regimens. The other is immunological complications, represented by GVHD. When anti-T-cell antibodies are included in conditioning regimens, the frequency of GVHD is decreased 19, 20 showing that GVHD is influenced by the types of preparative regimens. Given the fact that GVHD is the most common cause of nonrelapse death after RIST, 8 GVHD should be considered in the safety evaluation of conditioning regimens.
Another common complication after RIST is early progression of the underlying malignancy. This phenomenon could potentially be considered a consequence (and therefore toxicity) of the reduced intensity of the conditioning regimen.
Another consideration is the follow-up duration in evaluating immunological complications following RIST. The duration of observation after chemotherapy is usually 30 days. In contrast, the onset of GVHD can be delayed. The period of 30 days of observation is not long enough to evaluate the safety of RIST. Although the day 100 TRM has been used in RIST, it is not sufficient in evaluation of the immunological complications. We propose that TRM until day 200 should be used in the evaluation criteria for RIST-related toxicity.
Our study shows that both the Seattle criteria and NCI-CTC ver. 2.0 are useful in evaluating toxicity of RIST. Prospective studies are required to establish a proper toxicity grading system for RIST.
